Money Peak: Healthcare Sector Report

November 12 - November 19, 2025

💊 Overview of Market Developments

During the week of November 12 to November 19, 2025, the healthcare sector experienced a 0.84% increase, continuing its positive trend. This upward movement was largely driven by pharmaceutical companies, notably Merck & Co. with an impressive weekly rise of 3.84% and Johnson & Johnson with moderate growth of 0.21%. The strong performance was supported by significant mergers and acquisitions, including Johnson & Johnson's announcement to acquire biotechnology firm Halda Therapeutics for $3.05 billion to expand its oncology portfolio, as well as Merck's planned $9.2 billion acquisition of Cidara Therapeutics.

In contrast, healthcare service providers like UnitedHealth Group recorded a decline of 2.16%, illustrating the varied dynamics within the sector. This divergence highlights how regulatory developments and strategic corporate decisions create both winners and losers within the industry, with pharmaceutical innovators benefiting from portfolio expansions, while insurers face different challenges.

📊 Subsector Analysis

The performance of the healthcare sector exhibits distinct internal differences that investors should closely monitor. Pharmaceutical companies, with strategic acquisitions, led the positive trajectory, while healthcare service providers displayed mixed performance.

In the pharmaceutical sector, companies are increasingly focusing on strategic acquisitions to expand their product pipelines and safeguard against upcoming patent expirations. Oncology remains a central focus area, as demonstrated by the acquisitions of Johnson & Johnson and Merck. Simultaneously, innovative therapies for respiratory diseases are gaining importance, as evidenced by Merck's Cidara acquisition and Pfizer's engagement in the GLP-1 drug sector.

🏛️ Regulatory Landscape

The regulatory environment in the healthcare sector is evolving with several reform initiatives:

• The FDA approved AbbVie's EPKINLY in combination with Rituximab and Lenalidomide for relapsed or refractory follicular lymphoma, marking the first bispecific antibody combination therapy in lymphoma.

• The appointment of former FDA Commissioner Dr. Scott Gottlieb to the board of UnitedHealth Group signals a heightened focus on regulatory expertise amid changing healthcare policies.

• Medicare drug price negotiations now target insulin and selected high-priced medications, increasing pressure on the profit margins of pharmaceutical companies but also creating opportunities for firms with differentiated product profiles.

• The agreement between the U.S. government and pharmaceutical companies to reduce prices for GLP-1 medications for weight loss in exchange for tariff relief and expanded Medicare access represents a significant shift in drug pricing policy.

These developments collectively indicate an intensified focus on healthcare affordability, with the government balancing immediate price reductions against long-term innovation incentives—a delicate balance that will significantly impact the sector’s profitability.

🔬 Research & Development

In the area of clinical development, several promising advancements were made:

• Merck's WINREVAIR (sotatercept-csrk) achieved its primary endpoint in the Phase 2 CADENCE study among adults with combined post- and pre-capillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF), extending potential beyond the original indication.

• AbbVie's EPKINLY showed significantly superior progression-free survival and overall response rates compared to standard therapy in the Phase 3 EPCORE FL-1 study, with approximately three out of four patients achieving a complete response.

• Johnson & Johnson's acquisition of Halda Therapeutics adds HLD-0915 to their pipeline, a once-daily oral therapy for prostate cancer, which received the FDA's Fast Track designation in August 2025 following positive preliminary data from Phase 1/2 studies.

These advancements underscore the sector’s ongoing innovation capacity despite increasing price pressures and regulatory scrutiny.

🔮 Future Outlook

The healthcare sector faces both promising opportunities and significant challenges that will shape its development through the end of the year and into 2026:

• M&A activity is expected to remain high as major pharmaceutical companies diversify their pipelines and shield themselves against upcoming patent expirations. This could lead to further takeover bids for mid-sized biotech firms.

• The field of GLP-1 drugs remains a battleground where Pfizer, through its Metsera acquisition, seeks to compete with market leaders like Eli Lilly and Novo Nordisk.

• The defensive quality of healthcare stocks could continue to attract capital rotation out of the technology sector, especially if economic uncertainty increases.

• The balance between innovation and price control will remain a central theme, with companies possessing differentiated products and strong pipelines being better positioned to navigate regulatory pressures.

• Ongoing challenges in the health IT sector due to hospital budget constraints could accelerate mergers and consolidations in this subsector.

💡 Investment Recommendations

Based on our analysis, the following actions are advisable for investors:

1. Strategic Positioning in Oncology and Rare Diseases: Companies like Merck and Johnson & Johnson, enhancing their portfolios through targeted acquisitions in these areas, offer long-term growth prospects despite the overall price pressures in the healthcare sector.

2. Selective Approach to Healthcare Providers: Despite UnitedHealth's decline this week, strategic actions such as appointing regulatory experts to the board could yield long-term advantages in navigating evolving healthcare policies.

3. Observation of Dividend Strength: Companies like AbbVie and Pfizer with attractive dividend yields of 2.8% and 6.7%, respectively, offer defensive qualities with income potential in an uncertain market environment.

4. Caution with High-Valuation Biotech Stocks: Given the increasing M&A activity, investors should be wary of biotech companies whose valuations already reflect potential acquisitions and instead focus on firms with solid fundamentals and pipelines.

This report is solely for informational purposes and does not constitute individual investment advice. Investors should conduct their own due diligence and consider their personal risk tolerance before making investment decisions.